2 Dividend Stocks to Double up on This Week

NYSE: MYE | Myers Industries, Inc.  News, Ratings, and Charts

MYE – The stock market has been experiencing heightened volatility lately on concerns over the Fed’s aggressive rate hikes to tame record-high inflation and growing recession odds. Amid an uncertain market environment, investors increasingly take refuge in dividend stocks to ensure a steady income stream. Hence, it would be wise to invest in dividend stocks Myers Industries (MYE) and Pfizer (PFE). Continue reading….

Last week, the Fed didn’t just act in line with expectations of the third consecutive 75-bps interest rate hike; it also set expectations for further aggressive rate hikes until inflation is controlled. Moreover, Fed Chairman Jerome Powell acknowledged the economic pain this rapid monetary tightening may cause. “No one knows whether this process will lead to a recession or, if so, how significant that recession would be,” he said.

According to a model created by JPMorgan Chase & Co. strategists, S&P 500’s 6.5% rout since the Fed turned extremely hawkish last week implies a 92% probability of U.S. recession, up from 51% in August. With the fears of an economic slowdown and market volatility stuck in a vicious feedback loop, businesses seem to brace themselves for a rough ride ahead.

To dodge the elevated market volatility, investors should look for reliable stocks that provide consistent dividends for generating a stable income stream. So, high-yield dividend stocks Myers Industries, Inc. (MYE) and Pfizer Inc. (PFE) could be worth considering now.

Myers Industries, Inc. (MYE)

MYE is involved in manufacturing and distribution internationally. The company operates through two segments: Material Handling and Distribution.

On September 1, MYE announced the approval of a quarterly cash dividend of $0.135 per share which would be paid out on October 4, 2022. The company’s $0.54 per share forward annual dividend translates to a yield of 3.19% at the current price. This compares to a 4-year average dividend yield of 3.10%. The current payout ratio is 38.30%.

On June 1, MYE announced the acquisition of Mohawk Rubber Sales of New England Inc assets. The company expects Mohawk’s complementary geographic coverage, additional sales, and customer service capability to add value to its distribution segment and help it successfully execute its 3-horizon strategy.

For the second quarter of fiscal 2022 ended June 30, MYE’s net sales increased 24.4% year-over-year to $233.2 million. During the same period, the company’s adjusted operating income and net income increased 56.4% and 58.9% year-over-year to $23.62 million and $16.58 million, respectively. In addition, the adjusted net income per diluted share came in at $0.45, up 55.2% from the previous-year quarter.

Analysts expect MYE’s revenue and EPS for the fiscal year ending December 2022 to increase 18.9% and 62.4% year-over-year to $905.25 million and $1.58, respectively. Both metrics are expected to keep rising over the next two fiscals. The company has surpassed the consensus EPS estimates in three of its trailing four quarters.

MYE’s stock has gained 2.7% intraday to close the last trading session at $16.94.

MYE’s stable prospects are reflected in its POWR Ratings. The stock has an overall rating of B, translating to Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.

MYE also has a grade of B for Growth and Quality. It is ranked #5 of 36 stocks in the A-rated Industrial – Manufacturing industry.

Beyond what is stated above, we’ve also rated MYE for Value, Momentum, Sentiment, and Stability. Get all MYE’s ratings here.

Pfizer Inc. (PFE)

PFE is a world-renowned research-based biopharmaceutical company. The company discovers, develops, manufactures, sells, and distributes biopharmaceutical products, such as medicines, vaccines, and other therapies. The company operates through two segments: Biopharma and PC1.

On September 26, PFE and BioNTech SE (BNTX) announced the completion of the submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age. 

On September 22, PFE announced a cash dividend of $0.40 per common stock for the fourth quarter, payable on December 5, 2022. The company’s $1.60 per share forward annual dividend translates to a yield of 3.60% at the current price. The 4-year average dividend yield is 3.61%. Its dividends have increased at a CAGR of 5.7% over the past three years and 5.9% over the past five years.

PFE’s current payout ratio is 26%, and the company has increased its dividend for 11 consecutive years.

For the second quarter of the fiscal year 2022, PFE’s revenues increased 46.8% year-over-year to $27.74 billion. During the same period, adjusted income and EPS improved 93.5% and 92.5% year-over-year to $11.66 billion and $2.04, respectively.

Analysts expect PFE’s revenue and EPS for the fiscal year 2022 to increase 25% and 47% year-over-year to $101.57 billion and $6.50, respectively. Moreover, the company has an impressive earnings surprise history as it has topped the consensus EPS estimates in each of the trailing four quarters.

The stock has gained 3.2% over the past year to close the last trading session at $44.43.

PFE’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. It also has grade A for Value and grade B for quality.

It is ranked #10 in the 164-stock Medical – Pharmaceuticals industry. 

Click here to see the additional POWR Ratings for PFE (Growth, Momentum, Stability, and Sentiment).


MYE shares were trading at $16.76 per share on Thursday afternoon, down $0.18 (-1.06%). Year-to-date, MYE has declined -14.52%, versus a -22.73% rise in the benchmark S&P 500 index during the same period.


About the Author: Santanu Roy


Having been fascinated by the traditional and evolving factors that affect investment decisions, Santanu decided to pursue a career as an investment analyst. Prior to his switch to investment research, he was a process associate at Cognizant. With a master's degree in business administration and a fundamental approach to analyzing businesses, he aims to help retail investors identify the best long-term investment opportunities. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
MYEGet RatingGet RatingGet Rating
PFEGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

3 Auto Stocks to Consider Over TSLA in April

Tesla (TSLA) reported a decline in deliveries in the first quarter, and Wall Street expects the company to deliver fewer vehicles than last year. Furthermore, rising competition, slowing EV sales, and stretched valuation make TSLA unattractive from an investment standpoint. Considering these factors, investors could consider buying fundamentally strong auto stocks Blue Bird (BLBD), Rolls-Royce Holdings (RYCEY), and Stellantis (STLA) over Tesla (TSLA). Read more...

3 Top-Rated Tech Stock Buys for Value in April

The technology sector is undergoing a notable surge, propelled by increasing digitalization endeavors among businesses and governmental support for technological progress. So, fundamentally sound tech stocks Box Inc. (BOX), Teradata (TDC), and Materialise (MTLS), which seem pretty undervalued, might be ideal buys this month. Continue reading...

Top Software Stocks at the Forefront of Market Gains

The software industry's prospects appear bright due to increasing investments in digital transformation, high demand for advanced software services from various sectors, and the integration of emerging technologies such as generative AI. Therefore, investors could consider buying quality software stocks Autodesk (ADSK), DocuSign (DOCU), and Pegasystems (PEGA) for solid gains. Read more...

Does the Stock Market Have Indigestion?

The easy gains have already rolled in for the S&P 500 (SPY) to new heights. However, signs point to stocks entering a stage of “digestion”. What does that mean? And what does it tell us about investing in stocks the rest of the year? Steve Reitmeister shares his time views in this new market commentary including a preview of this top stocks to outperform. Get the full story below...

Read More Stories

More Myers Industries, Inc. (MYE) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All MYE News